FEATURED NEWS

Alzheimer’s: U.S. Health Care System Unprepared

U.S. health care system unprepared to move future Alzheimer’s treatment into rapid clinical use

“Addressing the capacity constraints may turn out to be as challenging as developing an effective treatment for Alzheimer’s,”

Advanced clinical trials are underway for at least 10 investigational therapies that have shown promise in slowing or blocking development of Alzheimer’s disease, creating hope that a preventive strategy may be in reach. But a new study warns that the U.S. health care system lacks the capacity to rapidly move such a treatment into wide clinical use, a shortcoming that could leave millions of people without access to transformative care if such a breakthrough occurs.

The U.S. health care system lacks the capacity to rapidly move a treatment for Alzheimer’s disease from approval into wide clinical use, a shortcoming that could leave millions of people without access to transformative care if such a breakthrough occurs, according to a new RAND Corporation study.

The primary problem is that there are too few medical specialists to diagnose patients who may have early signs of Alzheimer’s and confirm that they would be eligible for therapy to prevent the progression of the disease to full-blown dementia. Other shortcomings include a relatively low number of specialized diagnostic scanners and too few infusion centers to deliver treatments to patients.

Researchers estimate that as many as 2.1 million patients with mild cognitive impairment could develop Alzheimer’s dementia over a two-decade period while waiting for evaluation and treatment resources after approval of an Alzheimer’s disease-modifying therapy by the federal Food and Drug Administration.

“While significant effort is being put into developing treatments to slow or block the progression of Alzheimer’s dementia, little work has been done to get the medical system ready for such an advancement,” said Jodi Liu, lead author of the study and a policy researcher at RAND, a nonprofit research organization. “While there is no certainty an Alzheimer’s therapy will be approved soon, our work suggests that health care leaders should begin thinking about how to respond to such a breakthrough.”

An estimated 5.5 million Americans live with Alzheimer’s dementia today, with the number projected to increase to 11.6 million by 2040.

Advanced clinical trials are underway for at least 10 investigational therapies that have shown promise in slowing or blocking development of Alzheimer’s disease. Researchers say the progress provides guarded optimism that a disease-modifying therapy could become available for routine use within a few years.

Liu and her team examined the pathway patients would likely take to receive an Alzheimer’s therapy and created a model to simulate the pressures that such an approved therapy would put on the health care system.

The analysis assumes that a therapy is approved for use beginning in 2020 and screening would begin in 2019, although researchers stress that the date was chosen only as a scenario for the model, not as a prediction of when a therapy may be approved.

Under such a scenario, about 71 million Americans aged 55 and older would have to be screened for signs of mild cognitive impairment. After follow-up examinations and imaging to confirm evidence of Alzheimer’s, the RAND analysis estimates 2.4 million people ultimately could be recommended for treatment.

Researchers then analyzed how the activity might challenge the current health care system’s supply of dementia specialists, scanners used to identify Alzheimer’s abnormalities in the brain, and access to infusion centers that would deliver the treatment.

They found shortcomings in the capacity of all three areas of the health care system to cope with a surge in demand triggered by an initial Alzheimer’s therapy. Wait times to complete all three stages of the diagnostic and treatment phases would be 18.6 months in 2020, shrinking to 1.3 months in 2030 as the system develops more capacity and the surge in demand declines.

The analysis suggests several measures that could be taken to prepare for advent of an Alzheimer’s therapy.

To account for a shortage of neurologists and geriatricians, researchers suggest primary care physicians or mid-level providers such as nurse practitioners be trained to conduct initial screening for mild cognitive impairment. In addition, some primary care physicians and specialists such as general psychiatrists could become certified in dementia care to allow them to provide advanced testing and treatment. Use of telehealth also may play a role, researchers say.

Researchers suggest intensifying efforts to develop alternatives for PET scans, which are now the only FDA-approved diagnostic to confirm brain changes caused by Alzheimer’s. Options include further refining experimental tests that diagnose the illness using cerebrospinal fluid, as well as using mobile PET clinics to reach more patients.

The third potential bottleneck is a shortage of infusion centers where patients could receive medications. Most of the treatments under development for Alzheimer’s are biologic drugs that must either be injected or infused. While infusion centers may be able to ramp-up capacity quickly, a better option may be a combination of some clinic expansion, treatment in physician offices and home infusion. Such an approach might be able to meet the needs more quickly and at a lower cost, according to the analysis.

“Addressing the capacity constraints may turn out to be as challenging as developing an effective treatment for Alzheimer’s,” said Dr. Soeren Mattke, the study’s senior author and managing director of RAND Health Advisory Services. “But it is important to begin the discussion among stakeholders about how to start addressing the obstacles in a timely manner.”

The research was sponsored by Biogen, a biotechnology company that is working to develop a treatment for Alzheimer’s disease.

Story Source: RAND Corporation.


Journal Reference:

  1. Jodi L. Liu, Jakub P. Hlavka, Richard Hillestad, Soeren Mattke. Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer’s Treatment. RAND Research Reports, 2017; [link]
SPONSORIZED PARTNERS

WHAT'S TRENDING

Alzheimer’s: U.S. Health Care System Unprepared

U.S. health care system unprepared to move future Alzheimer’s treatment into rapid clinical use “Addressing the capacity constraints may turn out to be as challenging as developing an effective treatment for Alzheimer’s,” Advanced clinical trials are underway for at least 10 investigational therapies that have shown promise in slowing...

Continue reading

Health Topics

Higher thyroid hormone levels associated with artery disease and early death

High and high-normal levels of a thyroid hormone called FT4, were associated with artery disease and death in elderly and middle-aged people. “Our findings suggest that thyroid hormone FT4 measurement can help identify individuals at increased risk of atherosclerosis.” According to new research in Circulation Research, an American Heart...

Continue reading

Bonding benefits of breastfeeding extend years beyond infancy

Longer breastfeeding predicts increases in maternal sensitivity over time Women who breastfeed their children longer exhibit more maternal sensitivity well past the infant and toddler years, according to a 10-year longitudinal study published by the American Psychological Association. The results held even after accounting for maternal neuroticism, parenting attitudes,...

Continue reading

On Call with Dr. Lyons

As summer quickly comes to an end, our thoughts reluctantly begin to focus on Back to School. We start getting our homes “in order”, clothes and school supply shopping, cleaning out the summer sun, sand and fun of our thoughts so we can refocus our minds on the upcoming school year and all it brings. With that thought process, we tend to think about getting our health in order as well. Are the kids going to make it through the year “germ free”? Am I healthy enough to keep me and those around me going on the hectic schedule we call life?

In this issue we continue to give helping information about you and your family’s health. One very important part of keeping healthy is maintaining a healthy relationship with your family doctor. Cleveland Clinic gives us an informative perspective on this VIP we should all have access to (see page 16). Your Primary Care Physician (PCP) isn’t just for children, they should be your first resource in any stage of life and healthcare. Maintaining a long-term relationship with your PCP is a huge benefit in keeping you healthy.

As your thoughts turn to a seasonal change…we hope the information in this issue will continue to help you keep your healthcare goals.

Till next issue…

 

About What Doctors Know

Published by

What Doctors Know, LLC

Publisher and Chairman

Vicki J. Lyons, MD

Editorial and Design Director

Ran Stewart

Web and Digital Management

YourNext Services, LLC

Corporate Office
What Doctors Know
4403 Harrison Blvd. Suite 2855 Ogden, UT 84403 (801)512-0569

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

©2017 What Doctors Know

Log in with your credentials

Forgot your details?